Mukka Proteins to Acquire 51% Stake in Delta Marine Products for ₹11.10 Crore
Mukka Proteins will acquire a 51% stake in Delta Marine Products for up to ₹11.10 crore. The investment aims to expand the company's core business. Delta Marine Products had a turnover of ₹28.17 crore in FY25. The acquisition is expected to be completed by September 30, 2026.
The acquisition represents a significant investment and strategic expansion for Mukka Proteins, which could impact its market position and operational capabilities.
The acquisition is a strategic move to expand the company's core business, which is expected to improve production efficiency and market reach, indicating a positive outlook.
Mukka Proteins Limited announced today, June 12, 2026, that its Board of Directors has approved a strategic investment in Delta Marine Products, a partnership firm. The company will acquire a 51% stake in Delta Marine Products through capital contribution, not exceeding ₹11.10 crore (Rupees Eleven Crores Ten Lakhs Only), to be made in one or more tranches.
This investment is part of Mukka Proteins' strategic plan to expand its core business, focusing on capacity expansion and operational optimization to enhance production efficiency and market reach. Delta Marine Products is engaged in the manufacturing of fish meal and fish oil. For the financial year 2024-25, Delta Marine Products reported a turnover of ₹28.17 crore (Rs. 28,16,99,338) and a Profit After Tax (PAT) of ₹(19,72,919).
The acquisition is not a related party transaction. The indicative time period for the completion of the acquisition is September 30, 2026. Delta Marine Products was incorporated on August 12, 2023, and reported a turnover of ₹3.64 crore in FY2024 and ₹28.17 crore in FY2025. The acquired entity has its presence in India.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.